|
|
Article: Otsuka licenses domestic rights to B-MS' saxagliptin.(Otsuka Pharmaceutical)(Bristol-Myers Squibb Co)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- January 8, 2007
CopyrightCOPYRIGHT 2007 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Japan's Otsuka Pharmaceutical has been granted exclusive domestic rights to develop and commercialize US drug major Bristol-Myers Squibb's investigational compound saxagliptin, for the treatment of type 2 diabetes. Otsuka gains rights to the dipeptidyl peptidase-4 inhibitor, which is currently in Phase III development in the USA and Europe, in exchange for ...